Natural killer (NK) cells play an important role in the immunosurveillance of hematopoietic malignancies. Their reactivity is influenced by activating and inhibitory signals mediated by ...
A new research perspective titled "Targeting GITR in cancer immunotherapy—there is no perfect knowledge" has been published in Oncotarget. In this new perspective, researchers Diwakar Davar and ...
BUFFALO, NY- June 21, 2023 – A new research perspective was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.” ...
CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Leap Therapeutics, a company developing immuno-oncology therapeutics, reported results of a Phase 1 clinical trial of TRX518, an aglycosylated monoclonal agonist ...
GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not ...
The safety of oral uracil-tegafur plus leucovorin in the treatment of colorectal cancer in patients with partial DPD deficiency. Background: Glucocorticoid-induced tumor necrosis factor receptor (GITR ...
Inhibrx's technology may offer best-in-class approach for agonist antibodies New program further expands Five Prime's immuno-oncology pipeline and potential for combination therapies SOUTH SAN ...
Bristol-Myers quietly brings a novel combination to the big show. Eisai's blood vessel blocker compares well with standard of care in liver cancer. Details on GlycoMimetics AML data at ASCO. Good day, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results